» Articles » PMID: 35585528

Severe Disease Exacerbation After MRNA COVID-19 Vaccination Unmasks Suspected Multiple Sclerosis As Neuromyelitis Optica Spectrum Disorder: a Case Report

Overview
Journal BMC Neurol
Publisher Biomed Central
Specialty Neurology
Date 2022 May 18
PMID 35585528
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Since the beginning of the COVID-19 pandemic and development of new vaccines, the issue of post-vaccination exacerbation or manifestation of demyelinating central nervous system (CNS) disorders has gained increasing attention.

Case Presentation: We present a case of a 68-year-old woman previously diagnosed with multiple sclerosis (MS) since the 1980s who suffered a rapidly progressive severe sensorimotor paraparesis with loss of bladder and bowel control due to an acute longitudinal extensive transverse myelitis (LETM) after immunization with the mRNA Pfizer-BioNTech COVID-19 vaccine. Detection of Aquaporin-4-antibodies (AQP4) in both serum and CSF led to diagnosis of AQP4-antibody positive neuromyelitis optica spectrum disorder (NMOSD). Treatment with intravenous corticosteroids and plasmapheresis led to a slight improvement of the patient's symptoms.

Conclusions: Pathogenic mechanisms of post-vaccination occurrence of NMOSD are still unknown. However, cases like this should make aware of rare neurological disorders manifesting after vaccination and potentially contribute to improvement of management of vaccinating patients with inflammatory CNS disorders in the future. So far two cases of AQP4-antibody positive NMOSD have been reported in association with viral vector COVID-19 vaccines. To our knowledge, we report the first case of AQP4-antibody positive NMOSD after immunization with an mRNA COVID-19-vaccine.

Citing Articles

Cardiac and Neurological Complications Post COVID-19 Vaccination: A Systematic Review of Case Reports and Case Series.

Lee K, Yap S, Amin-Nordin S, Ngeow Y Vaccines (Basel). 2024; 12(6).

PMID: 38932303 PMC: 11209191. DOI: 10.3390/vaccines12060575.


New onset or relapsing neuromyelitis optica temporally associated with SARS-CoV-2 infection and COVID-19 vaccination: a systematic review.

Harel T, Gorman E, Wallin M Front Neurol. 2023; 14:1099758.

PMID: 37426444 PMC: 10323143. DOI: 10.3389/fneur.2023.1099758.


Effects of the COVID-19 Pandemic on Patients With NMO Spectrum Disorders and MOG-Antibody-Associated Diseases: COPANMO(G)-Study.

Hummert M, Butow F, Tkachenko D, Ayzenberg I, Pakeerathan T, Hellwig K Neurol Neuroimmunol Neuroinflamm. 2023; 10(2).

PMID: 36693760 PMC: 10108387. DOI: 10.1212/NXI.0000000000200082.


Comment on "The role of Epstein-Barr virus in multiple sclerosis: from molecular pathophysiology to in vivo imaging".

Asadollahzade E, Ghadiri F, Ebadi Z, Naser Moghadasi A Rev Assoc Med Bras (1992). 2022; 68(12):1624-1625.

PMID: 36449811 PMC: 9779949. DOI: 10.1590/1806-9282.20221201.

References
1.
Badrawi N, Kumar N, Albastaki U . Post COVID-19 vaccination neuromyelitis optica spectrum disorder: Case report & MRI findings. Radiol Case Rep. 2021; 16(12):3864-3867. PMC: 8512112. DOI: 10.1016/j.radcr.2021.09.033. View

2.
Chen S, Fan X, He S, Zhang J, Li S . Watch out for neuromyelitis optica spectrum disorder after inactivated virus vaccination for COVID-19. Neurol Sci. 2021; 42(9):3537-3539. PMC: 8241205. DOI: 10.1007/s10072-021-05427-4. View

3.
Cai H, Zhou R, Jiang F, Zeng Q, Yang H . Vaccination in neuromyelitis optica spectrum disorders: Friend or enemy?. Mult Scler Relat Disord. 2022; 58:103394. DOI: 10.1016/j.msard.2021.103394. View

4.
Fujikawa P, Shah F, Braford M, Patel K, Madey J . Neuromyelitis Optica in a Healthy Female After Severe Acute Respiratory Syndrome Coronavirus 2 mRNA-1273 Vaccine. Cureus. 2021; 13(9):e17961. PMC: 8516014. DOI: 10.7759/cureus.17961. View

5.
Langer-Gould A, Qian L, Tartof S, Brara S, Jacobsen S, Beaber B . Vaccines and the risk of multiple sclerosis and other central nervous system demyelinating diseases. JAMA Neurol. 2014; 71(12):1506-13. DOI: 10.1001/jamaneurol.2014.2633. View